Reduced Occurrence of Vertebral Crush Fractures in Senile Osteoporosis Treated with 1 Alpha (OH)-vitamin D3

Overview

Journal Bone Miner

Date 1987 Oct 1

PMID 3505192

Citations 22

Authors

H Orimo

M Shiraki

T Hayashi

T Nakamura

Affiliations

Soon will be listed here.

Abstract

To examine whether the administration of 1 alpha (OH)-vitamin D3 (1 alpha (OH)D3) could prevent the occurrence of vertebral crush fractures in senile osteoporosis, crush fractures of the thoracic or lumbar spine in senile osteoporosis treated with 1 alpha (OH)D3, 1.0 microgram/day (22 cases), 1 alpha (OH)D3 1.0 microgram/day + Ca 1.0 g/day (16 cases) or Ca 1.0 g/day (23 cases) were compared with those in non-treated controls (25 cases). The average treatment periods were 1.7 +/- 0.7 years in the 1 alpha (OH)D3 group, 2.1 +/- 1.0 years in the 1 alpha (OH)D3 + Ca group and 1.7 +/- 0.9 years in the Ca group. Occurrence of spinal crush fractures per 1000 patient years was significantly less in the 1 alpha (OH)D3 + Ca group (P less than 0.01) than in the non-treated control group. These findings suggest that administration of 1 alpha (OH)D3 is effective in preventing the occurrence of pathological fractures in senile osteoporosis.

Citing Articles

Update on pharmacologically-relevant vitamin D analogues.

Jones G, Kaufmann M Br J Clin Pharmacol. 2018; 85(6):1095-1102.

PMID: 30308088 PMC: 6533488. DOI: 10.1111/bcp.13781.

Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.

Avenell A, Mak J, OConnell D Cochrane Database Syst Rev. 2014; (4):CD000227.

PMID: 24729336 PMC: 7032685. DOI: 10.1002/14651858.CD000227.pub4.

Nuclear receptors and their selective pharmacologic modulators.

Burris T, Solt L, Wang Y, Crumbley C, Banerjee S, Griffett K Pharmacol Rev. 2013; 65(2):710-78.

PMID: 23457206 PMC: 11060414. DOI: 10.1124/pr.112.006833.

Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Brandi M Clin Cases Miner Bone Metab. 2012; 7(3):243-50.

PMID: 22460535 PMC: 3213838.

Clinical effect of bisphosphonate and vitamin D on osteoporosis: reappraisal of a multicenter double-blind clinical trial comparing etidronate and alfacalcidol.

Fujita T, Orimo H, Inoue T, Kaneda K, Sakurai M, Morita R J Bone Miner Metab. 2007; 25(2):130-7.

PMID: 17323183 DOI: 10.1007/s00774-006-0738-4.